The long-term (10.6 years) outcome of hepatitis c patients with sustained virologic response following treatment with pegylated interferon + ribavirin

Abstract

Objectives: Directly-acting anti-viral agents for the treatment of hepatitis C have been revolutionised. In the meantime, hepatitis C patients with sustained virologic response (SVR) achieved with previous treatments have been forgotten. Hepatitis C patients with SVR achived by pegylated interferon + ribavirin (INF + RIB) treatment are followed and it is investigated whether cirrhosis, hepatocellular carcinoma (HCC) and/or decompensation developed or not in these patients. Materials and Methods: One hundred thirty-five patients with hepatitis C virus who achieved SVR with pegylated INF alpha + RIB treatment between 2006 and 2010 are included in the study. At least twice a year, these patients were followed-up with ultrasonography, alpha fetoprotein and routine laboratory tests. Results: Out of the patients, 97.8% were genotype 1 and 95% were evaluated with biopsy before the treatment. One hundred twenty non-cirrhotic patients and 15 patients with compensated cirrhosis were followed for a period of 10.6 years (distribution: 9-13 years). None of the non-cirrhotic patients developed cirrhosis or HCC. HCC was developed in one of 15 cirrhotic patients (6 years after the treatment), resulting in the death of the patient. There were no decompensation case. Conclusion: It is evaluated that non-cirrhotic hepatitis C patients who achieved SVR with pegylated INF can be followed in a wider range of time. There should be a strict follow-up of cirrhotic patients, especially for HCC development.